Related Experiment Video

Updated: Jun 2, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases

Masahito Shimizu1, Seiji Adachi, Muneyuki Masuda

  • 1Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan. shimim-gif@umin.ac.jp

Molecular Nutrition & Food Research
|May 4, 2011
PubMed

Insights

Green tea catechins (GTCs), particularly EGCG, inhibit cancer cell growth by targeting receptor tyrosine kinases (RTKs). This research highlights GTCs as a promising strategy for cancer prevention by blocking key signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial for cell proliferation and are implicated in cancer development.
  • Green tea catechins (GTCs), especially (-)-Epigallocatechin-3-gallate (EGCG), are known for their potential anticancer properties.
  • EGCG's mechanism involves inhibiting the activation of RTKs, key regulators of cell growth.

Purpose of the Study:

  • To review the evidence linking GTCs to the inhibition of RTK activation.
  • To explore the role of EGCG in blocking specific RTKs like EGFR, IGF-1R, and VEGFR2.
  • To assess the potential of targeting RTKs with GTCs for cancer chemoprevention.

Main Methods:

  • Review of existing scientific literature on GTCs, RTKs, and cancer cell signaling.
  • Analysis of studies demonstrating EGCG's effects on EGFR, IGF-1R, and VEGFR2 activation.
  • Examination of preliminary trial data on GTCs in preventing precancerous lesions.

Main Results:

  • EGCG inhibits the proliferation and induces apoptosis in various cancer cells by blocking RTK activation, including EGFR, IGF-1R, and VEGFR2.
  • EGCG suppresses EGFR activation by disrupting membrane lipid organization, inhibiting receptor dimerization.
  • GTCs have shown success in preventing colorectal adenomas without significant adverse effects.

Conclusions:

  • GTCs exert anticancer and chemopreventive effects through the inhibition of specific RTKs.
  • Targeting RTKs and their signaling pathways with tea catechins presents a promising strategy for human cancer prevention.
  • Further research into GTCs as targeted cancer therapeutics is warranted.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...